TrialRheumatology (Oxford, England)2018

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Mark C Genovese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.